Connect with us

Business

FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals

Published

on

FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals


Food and Drug Administration Commissioner Marty Makary warned that the U.S. is falling behind China in early-stage drug development and called for reforms that could streamline the process for starting trials on new treatments. 

In an interview with CNBC on Wednesday, Makary specifically pointed to three bottlenecks that he said cause the U.S. to fall behind on those early drug trials. 

These include hospital contracting as well as ethical reviews and approvals, both of which he called “clunky processes that take too long and are leaving us noncompetitive with the countries that are moving a lot faster.” He also pointed to the process for submitting and receiving approvals for Investigational New Drug, or IND, applications, which companies submit to test a product in humans. 

“We walked into a mess,” Makary said, referring to how behind China the U.S. was in terms of Phase 1 clinical trials conducted in 2024. 

Food and Drug Administration Commissioner Marty Makary speaks in the Oval Office at the White House on Jan. 29, 2026.

Samuel Corum | Getty Images

He said the FDA is “looking at everything,” such as whether it can partner with health systems and academic medical centers on the pre-IND process. That refers to when companies consult the FDA before formally filing an application. 

Makary said the Trump administration should “partner with industry to help them deliver more cures and meaningful treatments for the American public because that is a common bipartisan goal that we all want. And we’re going to get it done in this administration.”

China’s biotech ecosystem has flourished over the last several years, driven by massive state investment, a vast talent pool and accelerated regulatory reforms. Once known for being a low-cost manufacturing base that pumps out copycats, China is rapidly evolving into a global innovation powerhouse. 

Data from Global Data and Morgan Stanley shows that China now conducts more clinical trials than the U.S., accounts for nearly a third of new global drug approvals and is on pace to reach 35% of FDA approvals by 2040. 

U.S. policymakers have been under pressure to take steps to boost innovation domestically. 



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

The two farms in Senegal that supply many of the UK’s vegetables

Published

on

The two farms in Senegal that supply many of the UK’s vegetables


Between January and March, if you browse the fresh produce aisles of the UK’s biggest food retailers, including Tesco, Sainsbury’s, Asda, Aldi and Lidl, you’re likely to see spring onions, radishes, green beans, chillis, butternut squash, and cobs of corn, all labelled Produce of Senegal.



Source link

Continue Reading

Business

Mark Zuckerberg arrives to testify in social media addiction trial

Published

on

Mark Zuckerberg arrives to testify in social media addiction trial


In one such case, 29 state attorney generals are pushing a California federal court to demand that the platforms make a number of changes immediately, before any trial, including forcing Meta to remove all accounts known to belong to users under 13 years of age.



Source link

Continue Reading

Business

India eyes diversification of crude oil sources; Piyush Goyal says would ‘love’ high-quality coking coal from US – The Times of India

Published

on

India eyes diversification of crude oil sources; Piyush Goyal says would ‘love’ high-quality coking coal from US – The Times of India


Goyal said India can produce goods in areas where US manufacturers may not be competitive.

India is looking to diversify its sources of crude oil, Commerce Minister Piyush Goyal has said. Goyal’s comments assume significance in light of the India-US trade deal joint statement which lowers tariffs on Indian exports to 18%. The Donald Trump administration has also removed the 25% penal tariffs on India on the condition that it stops buying crude oil from Russia.India’s crude imports from Russia have dropped since the US imposed sanctions on two major Russian oil firms in late 2025. According to reports, the share of Russian crude in India’s oil imports has dropped to the lowest level since late 2022 and analysts expect the numbers to drop further in the coming months.

India to Add $26 Trillion to Economy, Negotiating FTAs from Strength: Piyush Goyal

India would ‘love’ high-quality coking coal from US

Piyush Goyal said India is looking to broaden its sourcing of crude oil and coking coal and would welcome supplies of premium-quality coking coal from the United States.Also Read | 18% tariffs, boost to exports, agriculture protected: How India benefits from trade deal with US? Explained“We want to diversify our oil sources. I want to diversify the source of coking coal for example. I am dependent on 2 or 3 geographies (for that) and prices keep fluctuating. I would love to have American coking coal which is high quality coming to India,” he said according to a PTI report.He noted that the US is well positioned to supply several products that are critical for India’s economic growth, including graphics processing units used in artificial intelligence, infrastructure and equipment for data centres, and high-performance computing systems.Goyal said India can produce goods in areas where US manufacturers may not be competitive, while America can serve as an important provider of technology and investment capital.Also Read | Trump removes 25% penal tariff: What happens if India stops buying Russian crude oil?He added that demand for aircraft from the US is already estimated at about $100 billion over the next five years, with additional capacity required to expand domestic aviation and help lower fares.Under the proposed interim trade pact with the United States, India has conveyed its intent to procure goods worth $500 billion from America over the next five years. An Indian delegation is scheduled to travel to the US next week to conclude the legal drafting of the agreement, which is expected to be signed in March.Piyush Goyal said entering into a trade agreement with the US would be beneficial for India, noting that it would create significant opportunities for domestic businesses, particularly in labour-intensive sectors and technology-driven services.Referring to India’s free trade agreements, Goyal noted that nine such pacts have been concluded over the past four years. He added that these deals were negotiated from a position of confidence, emphasising that India now engages in trade talks assertively, without defensiveness, and with a focus on long-term interests.



Source link

Continue Reading

Trending